Benzinga | Jul 13, 2020 11:27AM EDT

Aegis Capital Initiates Coverage On ImmuCell with Buy Rating, Announces Price Target of $14

Aegis Capital analyst Nathan Weinstein initiates coverage on ImmuCell (NASDAQ:ICCC) with a Buy rating and announces Price Target of $14.